SCHEMBL14686526

SCHEMBL14686526

Clc1ccc(-c2cc(C3CCN(CCN4CCOCC4)CC3)n(-c3ccccc3)n2)cc1

nearest known ligand 0.61

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ PRCP P42785 6/20 0.61
▸ MEN1 O00255 2/20 0.48
▸ KMT2A Q03164 2/20 0.48
▸ KDM4E B2RXH2 1/20 0.48
▸ NPC1 O15118 1/20 0.48
▸ RAB9A P51151 1/20 0.48
▸ SMN1; SMN2 Q16637 1/20 0.48
▸ DRD2 P14416 6/20 0.47
▸ DRD4 P21917 6/20 0.47
▸ DRD3 P35462 5/20 0.45
▸ KDM5B Q9UGL1 1/20 0.45
▸ LMNA P02545 2/20 0.43
▸ GAA P10253 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ ACHE P22303 1/20 0.43
▸ AVPR1B P47901 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12185619 0.87 PRCP (0.79) PRCPMEN1KMT2AKDM4ENPC1
SCHEMBL14686651 0.87 PRCP (0.76) PRCPMEN1KMT2AKDM4ENPC1
SCHEMBL14686768 0.84 PRCP (0.57) PRCPMEN1KMT2ADRD2DRD4
SCHEMBL12185630 0.83 PRCP (0.69) PRCPMEN1KMT2AKDM4ENPC1
SCHEMBL12185531 0.83 PRCP (0.69) PRCPMEN1KMT2ADRD2DRD4
SCHEMBL12185593 0.81 PRCP (0.72) PRCPMEN1KMT2AKDM4ENPC1
SCHEMBL14691670 0.80 PRCP (0.69) PRCPDRD2DRD4DRD3MAPT
SCHEMBL12185553 0.79 PRCP (0.73) PRCPMEN1KMT2ADRD2DRD4
SCHEMBL12185603 0.79 PRCP (0.60) PRCPMEN1KMT2AKDM4ENPC1
SCHEMBL12185591 0.78 PRCP (0.69) PRCPMEN1KMT2ADRD2DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2568812-B1 NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS MERCK SHARP & DOHME (US) 2016-10-26 — — EP disclosed
EP-2568812-B1 NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS MERCK SHARP & DOHME (US) 2016-10-26 — — EP disclosed
US-9365539-B2 Prolylcarboxypeptidase inhibitors MERCK SHARP & DOHME CORP. (US) 2016-06-14 — — US disclosed
US-9365539-B2 Prolylcarboxypeptidase inhibitors MERCK SHARP & DOHME CORP. (US) 2016-06-14 — — US disclosed
US-9365539-B2 Prolylcarboxypeptidase inhibitors MERCK SHARP & DOHME CORP. (US) 2016-06-14 — — US disclosed
US-20130040929-A1 NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2013-02-14 — — US disclosed
US-20130040929-A1 NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2013-02-14 — — US disclosed
US-20130040929-A1 NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2013-02-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130040929-A1 NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS PRCP, PREP, ENPEP PRCP 1/4885MEN1 3238/4885KMT2A 2172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback